GANX
Gain Therapeutics Inc
NASDAQ: GANX · HEALTHCARE · BIOTECHNOLOGY
$1.80
-8.60% today
Updated 2026-06-05
Market cap
$72.51M
P/E ratio
—
P/S ratio
255.50x
EPS (TTM)
$-0.58
Dividend yield
—
52W range
$1 – $4
Volume
0.6M
Gain Therapeutics Inc (GANX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-151.64%
ROA
-81.20%
Debt/equity
0.02x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $20609.00 | $-1.11M | 100.00% | -4,989.66% | -5,364.36% |
| 2019 | $41301.00 | $-2.19M | 100.00% | -5,084.89% | -5,310.88% |
| 2020 | $28881.00 | $-3.58M | 100.00% | -12,047.54% | -12,387.67% |
| 2021 | $164994.00 | $-13.89M | 100.00% | -8,379.80% | -8,418.86% |
| 2022 | $140108.00 | $-17.59M | 100.00% | -12,688.10% | -12,555.13% |
| 2023 | $55180.00 | $-22.27M | 100.00% | -40,328.26% | -40,354.33% |
| 2024 | $0.00 | $-20.41M | — | — | — |
| 2025 | $0.00 | $-20.16M | — | — | — |
Frequently asked questions
How much free cash flow does GANX generate?
GANX produced $-18.47M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is GANX's balance sheet healthy?
GANX holds $20.84M in cash and equivalents against $300084.00 in long-term debt, on $18.56M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.